Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
George West Mental Health Foundation d/b/a Skyland Trail
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06328140CT.gov Sleep Quality, Cognitive Performance, and Computerized Cognitive Training | — | Withdrawn | — | — | — |
NCT05480150CT.gov Chinese Longitudinal and Systematic Study of Bioplar Disorder | — | Recruiting | — | — | — |
NCT02731612CT.gov Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients | — | Completed | — | — | — |
NCT01932541CT.gov Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old | — | Withdrawn | — | — | — |
NCT02893371CT.gov Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies | — | Terminated | — | — | — |
NCT01498770CT.gov An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) | — | Completed | — | — | — |
NCT01485640CT.gov Lurasidone Extended Use Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lurasidone (this asset) | George West Mental Health Foundation d/b/a Skyland Trail | Approved | BB · 69 |
| Asenapine | Dr. Stavroula Rakitzi | P4 | BBB |
| Citalopram | University of Texas Southwestern Medical Center | P4 | BBB |
| Escitalopram | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Lithium, Elemental | University of Aarhus | P4 | BBB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BBB |
| Paroxetine | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | P4 | BBB |
| Lamotrigine | Johns Hopkins University | P4 | BBB |
| Valproic Acid | University of New Mexico | P4 | BBB |
+42 more in the Bipolar Disorder cohort
Other indications for Lurasidone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Depression | — | P4 | A · 82 |
| Bipolar I Disorder | — | P4 | BBB · 79 |
| Schizoaffective Disorder | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lurasidone in Bipolar Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lurasidone-bipolar-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →